Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

SB 1356Sesión 2025

Qué cambió entre versiones

221 párrafos cambiaron+348 palabras agregadas−339 eliminadas

El texto resaltado se agregó en la versión más reciente. El texto tachado se eliminó.

Florida Senate

-

2025

CS for CS for SB 1356

By

the CommitteeCommittees on Fiscal Policy; and Education Postsecondary; and Senator Burton

and Senators Burton and Berman

589-02481-25594-03194-25 20251356c120251356c2

1 A bill to be entitled

3 párrafos sin cambios

2 An act relating to the Florida Institute for Pediatric

3 Rare Diseases; creating s. 1004.4211, F.S.;

4 establishing the Florida Institute for Pediatric Rare

5 Diseases within the Florida State University College

6 of Medicine; providing the goalspurpose of the institute;

7 providing the goals of the institute; requiring the

78 requiring the institute to establish and administer the Sunshine

89 the Sunshine Genetics Pilot Program for a specified period;

910 period; providing the purpose of the pilot program; providing

1011 providing institute responsibilities and duties relating to the

1112 relating to the pilot program; providing requirements for

1213 for participation in the pilot program and data collection

1314 collection and release in the pilot program; defining the term

1415 the term “health care practitioner”; providing reporting

1516 reporting requirements for the pilot program; establishing the

1617 establishing the Sunshine Genetics Consortium for specified purposes;

1718 specified purposes; requiring the consortium to be administered at the

1819 administered at the institute by an oversight board; providing for the

1920 providing for the membership and terms of the board; providing reporting

21 requirements for the consortium; specifying that

22 implementation of the act is subject to appropriation;

2023 providing meetingan andeffective reporting requirements for thedate.

21 consortium; providing appropriations; providing an

22 effective date.

2324

2425 Be It Enacted by the Legislature of the State of Florida:

2526

2627 Section 1. Section 1004.4211, Florida Statutes, is created

2728 to read:

2829

1004.4211

The Florida Institute for Pediatric Rare

29

30

Diseases; the Sunshine Genetics Pilot Program; the Sunshine

3031

Genetics Consortium.—

3132

(1)

The Florida Institute for Pediatric Rare Diseases is

3233

established within the Florida State University College of

3334

Medicine as a statewide resource for pediatric rare disease

3435

research and clinical care. The purpose of the institute is to

3536

improve the quality of life and health outcomes for children and

3637

families affected by rare diseases by advancing knowledge,

3738

diagnosis, and treatment of pediatric rare diseases through

3839

research, clinical care, education, and advocacy.

39

40

(2)

The goals of the institute are to:

4041

(a)

Conduct research to better understand the causes,

4142

mechanisms, and potential treatments for pediatric rare

4243

diseases, including leveraging emerging research methods.

4344

(b)

Develop advanced diagnostic and genetic screening tools

4445

and techniques to enable health care providers to identify rare

4546

diseases in newborns and children more rapidly, accurately, and

4647

economically.

4748

(c)

Provide comprehensive multidisciplinary clinical

4849

services and care for children with rare diseases. Such care may

49

50

include, but is not limited to, patient, family, and caregiver

5051

support and resources to help navigate the challenges associated

5152

with these conditions, support groups, and patient advocacy.

5253

(d)

Educate and train health care professionals, including,

5354

but not limited to, genetic counselors, pediatricians,

5455

scientists, and other specialists in the field of pediatric rare

5556

diseases.

5657

(e)

Establish collaborations with other research

5758

institutions, medical centers, patient and family advocacy

5859

organizations, and government agencies whenever deemed

59

60

appropriate by the institute director to share expertise, raise

6061

awareness, and promote a collective effort to tackle pediatric

6162

rare diseases.

6263

(3)(a)

The institute shall establish and administer the

6364

Sunshine Genetics Pilot Program to be administered for a period

6465

of 5 years. The pilot program shall provide newborn genetic

6566

screening, including, but not limited to, whole genome

6667

sequencing. Genetic screening shall be performed by the

6768

institute and institutional members of the oversight board upon

6869

approval of the oversight board.

69

70

(b)

The institute may establish partnerships with Florida

7071

universities and colleges and health care service providers to

7172

promote and assist in the implementation of the pilot program.

7273

(c)

The pilot program shall be an opt-in program and a

7374

parent of a newborn must provide consent to participate in the

7475

pilot program.

7576

(d)

The institute and institutional members of the

7677

oversight board shall release clinical findings of a newborn’s

7778

screening to the newborn’s health care practitioner and the

7879

newborn’s parent. As used in this paragraph, the term “health

79

80

care practitioner” means a physician or physician assistant

8081

licensed under chapter 458; an osteopathic physician or

8182

physician assistant licensed under chapter 459; an advanced

8283

practice registered nurse, registered nurse, or licensed

8384

practical nurse licensed under part I of chapter 464; a midwife

8485

licensed under chapter 467; a speech-language pathologist or

8586

audiologist licensed under part I of chapter 468; a dietitian or

8687

nutritionist licensed under part X of chapter 468; or a genetic

8788

counselor licensed under part III of chapter 483.

8889

(e)

The institute shall:

8990

1.

Maintain a secure database to collect and store all

9091

pilot program data, including, but not limited to, newborn

9192

genomics sequence data and deidentified newborn data.

9293

2.

Provide deidentified newborn data to members of the

9394

consortium pursuant to a data sharing agreement to support

9495

ongoing and future research.

9596

(f)

By December 1, 2030, the institute shall provide a

9697

report on the Sunshine Genetics Pilot Program to the Governor,

9798

the President of the Senate, and the Speaker of the House of

9899

Representatives. The report must include, at a minimum:

99

100

1.

Study population and enrollment metrics.

100101

2.

Whole genome sequencing metrics.

101102

3.

Clinical and public health impact.

102103

4.

Cost effectiveness and economic benefits.

103104

(4)(a)

The Sunshine Genetics Consortium is established to

104105

create a network of clinical and academic research

105106

professionals, geneticists, and physicians from state

106

universities and the state’s children’s hospitals to collaborate

107

with leaders in the genetic industry and build and support a

universities and this state’s children’s hospitals to

108

culture of collaborative research and the development of cutting

collaborate with leaders in the genetics industry and build and

109

edge genetic and precision medicine in the state. The consortium

support a culture of collaborative research and the development

110

shall:

of cutting-edge genetic and precision medicine in the state. The

111

consortium shall:

112

1.

Integrate state-of-the-art genomic sequencing

112113

technologies.

113114

2.

Advance research and the development of cutting edgecutting-edge

114115

genetic and precision medicine.

115116

3.

Leverage advancements in artificial intelligence

116117

utilization in genomics.

117118

4.

Develop educational opportunities for clinicians on

118119

genomic tools.

119

120

5.

Support the growth and education of geneticists to meet

120121

demand.

121122

6.

Solicit and leverage funds from nonprofits, private

122123

industry, and others for the purpose of expanding the Sunshine

123124

Genetics Pilot Program and to support genetic screenings by

124125

institutional members of the oversight board.

125126

7.

Promote patient care that supports families with

126127

children diagnosed with genetic disorders.

127128

8.

Report on the use of deidentified newborn data by

128129

members of the consortium.

129

130

(b)1.

The consortium shall be administered at the institute

130131

by an oversight board. The board shall convene at least once

131132

every 6 months.

132133

2.

The oversight board for the consortium shall consist of

133

the director of the institute who shall serve as chair and the

134

followingthe votingdirector membersof the institute, who shall serve 2-yearas terms:chair, and the

135

following voting members, who shall serve 2-year terms:

136

a.

One member nominated by the dean of the University of

136137

Florida’s College of Medicine and approved by the university’s

137138

president.

138139

b.

One member nominated by the dean of the University of

139

140

South Florida’s College of Medicine and approved by the

140141

university’s president.

141142

c.

One member nominated by the dean of the University of

142143

Miami’s School of Medicine and approved by the university’s

143144

president.

144145

d.

One member nominated by the dean of Florida

146

International University’s School of Medicine and approved by

147

the university’s president.

148

e.

One member nominated by Nicklaus Children’s Hospital and

149

approved by the hospital’s president and chief executive

150

officer.

151

f.

One member appointed by the Governor.

145152

eg.

One member appointed by the President of the Senate.

146

153

fh.

One member appointed by the Speaker of the House of

147154

Representatives.

148

155

3.

The board shall be responsible for the promotion and

149

156

oversight of the consortium, including, but not limited to, the

150157

nomination and appointment of members of the consortium.

151158

(c)

Beginning October 15, 2026, and annually thereafter,

152159

the consortium shall provide a report to the Governor, the

153

160

President of the Senate, and the Speaker of the House of

154

161

Representatives on research projects, research findings,

155

162

community outreach initiatives, and future plans for the

156163

consortium.

157 Section 2.

For the 2025-2026 fiscal year, the sum of $5

158

million in recurring funds is appropriated from the General

159

Revenue Fund to the Florida Institute for Pediatric Rare

160

Diseases.

161 Section 3.

For the 2025-2026 fiscal year, the sum of $20

162

million in nonrecurring funds is appropriated from the General

163

Revenue Fund to the Florida Institute for Pediatric Rare

164

Diseases for the implementation of the Sunshine Genetics Pilot

(5)

The provisions of this section shall be implemented to

165

Program established in s. 1004.4211, Florida Statutes.

the extent of available appropriations contained in the annual

166

General Appropriations Act for such purpose.

166167 Section 42. This act shall take effect July 1, 2025.

Volver al texto completo